Novel SARS-CoV-2 neutralizing antibodies

Therapeutic candidates retain binding to major COVID-19-causing “South African” variant

Register for free to listen to this article
Listen with Speechify
Novel SARS-CoV-2 neutralizing antibodies

IONTAS has identified antibody candidates that might be able to combat newer variants of the SARS-CoV-2 virus.

CAMBRIDGE, UK, PORTO, Portugal & LONDON—IONTAS Ltd., which focuses on the discovery and optimization of fully human antibodies, has announced the identification of neutralizing antibodies that bind to multiple emerging SARS-CoV-2 variants. 

The results, generated from a combination of phage display technology and B cell receptor repertoire sequencing of hospitalized COVID-19 patients, have identified what the company calls “potent neutralizing antibodies with distinct mechanisms of action.” Based on this approach and its work with biologics-focused contract research organization FairJourney Biologics S.A, IONTAS has developed a panel of therapeutic candidates. 

SARS-CoV-2 virus enters the body as a result of the viral spike protein binding to the ACE2 protein on the surface of lung cells. This interaction is driven by a small region of the spike protein and the majority of antibodies currently undergoing clinical trial bind to this site. However, this site has changed in some of the emerging viral variants, reducing or abolishing the effect of some clinical candidates. Drug candidate antibodies developed by IONTAS to this same site have been shown to retain binding to the emerging variants. 

An alternative approach for tackling variants is to target alternative regions of the virus that have a greater degree of conservation, making escape variants less likely. GSK/VIR Biotechnology recently announced a successful Phase 3 trial of such an antibody. VIR-7831 is an antibody which binds to a region of the spike protein which is highly conserved between SARS-CoV-2 and SARS-CoV-1 (A distantly related virus responsible for the outbreak of severe acute respiratory syndrome in 2003). VIR-7831 has shown an 85-percent reduction in hospitalization and death during the COMET-ICE clinical trial. 

A subset of the IONTAS antibodies show a similar functionality to VIR-7831 by binding to sites conserved both in the recently emerging SARS-CoV-2 variants as well as to the more distantly related SARS-CoV-1 virus.

“The first wave of antibody drugs for treating COVID-19 was focused on achieving maximal neutralization to the original SARS-CoV-2 strain first identified in Wuhan. This led many companies to a target site on the virus which is very effective for neutralization but also prone to genetic change,” explained Dr. John McCafferty, chief scientific officer at IONTAS. “Second-generation drug candidates need to anticipate the emergence of new variants by targeting more conserved sites. IONTAS has identified drug candidates which neutralize by targeting conserved regions of the virus. We now seek partners to help develop these to better position the world in tackling this dreadful disease.”



FairJourney Biologics S.A.

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue